March 2020 I Euronext, EPA: ALBPS
Forward Looking Statements All statements pertaining to future financial and/or operating results, future growth in research, clinical development, and potential opportunities for Biophytis SA and its subsidiaries (the “Company”) and its products, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to, statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates”) should also be considered to be forward - looking statements. By their nature, forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and other risks, please refer to the Risk Factors (“Facteurs de Risque”) section of the Listing Prospectus upon the admission of Company’s shares for trading on the regulated market Euronext Growth of Euronext Paris filed with the AMF, which is available on the AMF website (www.amf-france.org ) or on the Company’s website ( www.biophytis.com). Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the Company's business. Any forward-looking statements that we make in this presentation speak only as of the date of such statement, and we undertake no obligation to update such statements to reflect events or circumstances after the date of this presentation, except as required by law. 2
A clinical-stage biotechnology company in age-related diseases Our goal Neuromuscular diseases Retinal diseases Pre-clinical drug candidates Lead candidate BIO101 (Sarconeos) Prevent disabilities (mobility and Macuneos (BIO201, BIO203) developed in : vision) and increase health span Sarcopenia: Clinical Phase 2b for diseases of the retina, for patients suffering from age- such as Dry Age-related Macular A geriatric chronic muscular related diseases Degeneration (AMD) and dystrophy Small molecules derived from Stargard’s disease Duchenne’s Muscular Dystrophy plants which stimulate biological (DMD): IND granted resilience developed by reverse A pediatric genetic muscular Animal POC obtained pharmacology dystrophy 3
Modern drug discovery process, inspired by traditional medicine Our technology Reverse pharmacology for drug candidates ▪ BIO 101: Muscular Dystrophy ▪ BIO 201:Retinopathy in Age Related diseases ▪ Followed by BIO103 & BIO203 Build a proprietary Screen in Selection of collection of • Small molecules: natural cellular models best drug natural molecules of age related candidates and/or NCE & analogs from diseases and based on • New target key for aging medicinal plant, identification animal models produced under • Preclinical proof-of- of targets & of aging or biotic or abiotic concept & safety pathways genetic diseases stress • IP on use, process and composition of matter DAPI MHC 4
Our clinical pipeline for worldwide development • Second generation drug candidates, BIO103 and BIO203, are life-cycle extension candidates in the preclinical Phase 5
Executive team Samuel Agus - CMO Stanislas Veillet - Founder & CEO • MD, PhD, Board-certified Neurologist • PhD in genetics, AgroParisTech • 15+ years pharma/biotech experience • 25+ years in biotech; Pharmacia-Monsanto, including Abbott, Shire and Teva Danone Group Pharmaceuticals Manfred Horst - BD Officer Pierre Dilda - CSO • • MD, PhD, MBA 20+ years experience in pharmaceutical research, in both academic and industrial • 30+ years pharma experience; including Ciba- settings Geigy/Novartis and 12 years BD for Merck & Co. • 50+ scientific publications Evelyne Nguyen- CFO Wally Dioh - COO • 25+ years of experience in Corporate Finance for • PhD in phytopathology (Paris XI) and MBA International Pharma & Biotech companies ( BMS, • 21+ years biotech experience in France and the LFB) U.S. and R&D at Monsanto • Expertise in cross-borders transactions between Europe, US and Asia 6
Scientific advisory board Pr. Jean Mariani Dr. Roger Fielding • • Professor of neuroscience and biology of aging Professor of Medicine, Tufts University School of and Director of Charles Foix Institute of Medicine Longevity at Sorbonne University • Director and Sr. Scientist Jean Mayer USDA Human • Emeritus Professor (PU-PH) at the Sorbonne Nutrition Research Center on Aging University’s School of Medicine • Member of the Board and Executive committee of Gerond’IF René Lafont Dr. Thomas Voit • Professor emeritus and former Dean of the life • Professor, University College London sciences department at Sorbonne University • Director of the Research Centre of the Great Ormond • 185 scientific articles + 59 reviews and book Street Hospital for Children chapters Dr. Ivana Kim Pr. Jose-Alain Sahel • Associate Professor Harvard Medical School, • Chair of the department of ophthalmology Massachusetts Eye and Ear at University of Pittsburgh School of • Co-Director of the Harvard Medical School Medicine and director of the UPMC eye Department of Ophthalmology AMD Center of center Excellence; Associate Scientist, Massachusetts Eye • Founder and director of the Vision Institute and Ear in Paris and professor at the Sorbonne’s medical school 7
Board of directors Stanislas Veillet - Founder & CEO Pr. Jean Mariani • PhD in genetics, AgroParisTech • Professor of neuroscience and biology of aging • and Director of Charles Foix Institute of 25+ years in biotech; Pharmacia-Monsanto, Danone Longevity at Sorbonne University Group • Emeritus Professor (PU-PH) at the Sorbonne University’s School of Medicine • Member of the Board and Executive committee of Gerond’IF Jean M. Franchi Dimitri Batsis • • Merrimack Pharma CFO Entrepreneur • • Founder of Zeni Corporation, Drone Volt 30+ years as finance director, including 15 years at Genzyme • 20 years in the technology sector Nadine Coulm • IR Director for Korian • 20 years of IR experience with FNAC, BNP Paribas, Danone & Casino 8
From a Sorbonne University spin-off to a successful clinical-stage biotechnology company • Initiated SARA- INT Phase 2b • IPO on Alternext clinical trial Paris that raised • Incorporated on • Received orphan €10.0 M Sept 26, 2006 drug designation • Opened U.S. • First patents for Sarconeos subsidiary in filed in 2007 (BIO101) in DMD Cambridge, MA • Raised €800 K in US and Europe • Raised €6.0M in with Seventure • Raised €10M in private Partners notes placement 2006 - 2008 2009- 2012 2015 2016-2017 2018 2019 • 2016 initiated • 2009 €2.2 M • Set up €24M and completed Round A with bond financing SARA-PK Phase 1 VC’s • Filed and clinical trial • 2009 launched granted IND for • 2017 raised first human Sarconeos €18.0 M in clinical trials for (BIO101) in DMD private Sarconeos placements (BIO101) • Set up €15M • 2012 €3.0 M bond financing Round B with • Initiated SARA- VC’s OBS clinical trial 9
Overview Sarconeos (BIO101) for sarcopenia Sarconeos (BIO101) for DMD Macuneos (BIO201) for dry AMD 10
Sarcopenia: a large unmet medical need with no approved drug • Age-related degeneration of skeletal muscle characterized by a loss of muscle mass, strength and functional issues such as the ability to stand and/or walk • A major cause of mobility disability, resulting in a loss of independence and increased risk of adverse events (falls) , which can shorten life expectancy Sarconeos (BIO101): ✓ Only drug candidate currently being tested in Phase 2 for sarcopenia ✓ Myostatin inhibitors halted for lack of efficacy in neuromuscular diseases China Europe USA Japan Total 324.2 M 126.5 M 1,392.7 M 511.5 M Population Population 99.2 M 34.9 M 152.1 M 47.8 M over 65 6 – 22 % 6 – 22 % 6 – 22 % 6 – 22 % Prevalence Potential 9.1 -33.5 6.0 -21.8 2.9 -10.5 2.1 - 7.7 Patient M M M M Population 11
Sarconeos (BIO101) activates MAS receptor, a key factor for muscle metabolism • MAS receptor: a key component of the Renin-Angiotensin System (RAS) • Trigger two important downstream pathways in myocytes: MAS PI3K/AKT/mTOR: Increases protein synthesis, Receptor preserving muscle mass and increasing muscle strength AMPK/ACC Stimulates energy production , increasing muscle strength and mobility Protein Energy Synthesis Production AKT AMPK Pathway Pathway 12
Recommend
More recommend
